These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 23403076)
1. Imaging integrin α(v)β(3) positive glioma with a novel RGD dimer probe and the impact of antiangiogenic agent (Endostar) on its tumor uptake. Wu H; Chen H; Sun Y; Wan Y; Wang F; Jia B; Su X Cancer Lett; 2013 Jul; 335(1):75-80. PubMed ID: 23403076 [TBL] [Abstract][Full Text] [Related]
2. Tumor uptake of the RGD dimeric probe (99m)Tc-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature. Liu Z; Jia B; Shi J; Jin X; Zhao H; Li F; Liu S; Wang F Bioconjug Chem; 2010 Mar; 21(3):548-55. PubMed ID: 20184307 [TBL] [Abstract][Full Text] [Related]
3. Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers. Wang L; Shi J; Kim YS; Zhai S; Jia B; Zhao H; Liu Z; Wang F; Chen X; Liu S Mol Pharm; 2009; 6(1):231-45. PubMed ID: 19067525 [TBL] [Abstract][Full Text] [Related]
4. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640 [TBL] [Abstract][Full Text] [Related]
5. Multimeric system of 99mTc-labeled gold nanoparticles conjugated to c[RGDfK(C)] for molecular imaging of tumor α(v)β(3) expression. Morales-Avila E; Ferro-Flores G; Ocampo-García BE; De León-Rodríguez LM; Santos-Cuevas CL; García-Becerra R; Medina LA; Gómez-Oliván L Bioconjug Chem; 2011 May; 22(5):913-22. PubMed ID: 21513349 [TBL] [Abstract][Full Text] [Related]
6. Anti-tumor effect of integrin targeted (177)Lu-3PRGD2 and combined therapy with Endostar. Shi J; Fan D; Dong C; Liu H; Jia B; Zhao H; Jin X; Liu Z; Li F; Wang F Theranostics; 2014; 4(3):256-66. PubMed ID: 24505234 [TBL] [Abstract][Full Text] [Related]
7. Specific uptake of 99mTc-NC100692, an αvβ3-targeted imaging probe, in subcutaneous and orthotopic tumors. Dearling JL; Barnes JW; Panigrahy D; Zimmerman RE; Fahey F; Treves ST; Morrison MS; Kieran MW; Packard AB Nucl Med Biol; 2013 Aug; 40(6):788-94. PubMed ID: 23701702 [TBL] [Abstract][Full Text] [Related]
8. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression. Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166 [TBL] [Abstract][Full Text] [Related]
9. In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD. Sancey L; Ardisson V; Riou LM; Ahmadi M; Marti-Batlle D; Boturyn D; Dumy P; Fagret D; Ghezzi C; Vuillez JP Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):2037-47. PubMed ID: 17674000 [TBL] [Abstract][Full Text] [Related]
10. Monitoring glioma growth and tumor necrosis with the U-SPECT-II/CT scanner by targeting integrin αvβ3. Shao G; Zhou Y; Wang F; Liu S Mol Imaging; 2013; 12(1):39-48. PubMed ID: 23348790 [TBL] [Abstract][Full Text] [Related]
11. Design and biological evaluation of ⁹⁹mTc-N₂S₂-Tat(49-57)-c(RGDyK): a hybrid radiopharmaceutical for tumors expressing α(v)β(3) integrins. Ocampo-García BE; Santos-Cuevas CL; De León-Rodríguez LM; García-Becerra R; Ordaz-Rosado D; Luna-Guitiérrez MA; Jiménez-Mancilla NP; Romero-Piña ME; Ferro-Flores G Nucl Med Biol; 2013 May; 40(4):481-7. PubMed ID: 23618768 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. Liu S; Hsieh WY; Jiang Y; Kim YS; Sreerama SG; Chen X; Jia B; Wang F Bioconjug Chem; 2007; 18(2):438-46. PubMed ID: 17341108 [TBL] [Abstract][Full Text] [Related]
13. Imaging of Integrin α Song YS; Park HS; Lee BC; Jung JH; Lee HY; Kim SE Cancer Biother Radiopharm; 2017 Oct; 32(8):288-296. PubMed ID: 29053416 [TBL] [Abstract][Full Text] [Related]
15. 99mTc-labeled cyclic RGDfK dimer: initial evaluation for SPECT imaging of glioma integrin alphavbeta3 expression. Jia B; Shi J; Yang Z; Xu B; Liu Z; Zhao H; Liu S; Wang F Bioconjug Chem; 2006; 17(4):1069-76. PubMed ID: 16848417 [TBL] [Abstract][Full Text] [Related]
16. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide. Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129 [TBL] [Abstract][Full Text] [Related]
17. The feasibility of 18F-AlF-NOTA-PRGD2 PET/CT for monitoring early response of Endostar antiangiogenic therapy in human nasopharyngeal carcinoma xenograft model compared with 18F-FDG. Cui Y; Liu H; Liang S; Zhang C; Cheng W; Hai W; Yin B; Wang D Oncotarget; 2016 May; 7(19):27243-54. PubMed ID: 27029065 [TBL] [Abstract][Full Text] [Related]
18. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743 [TBL] [Abstract][Full Text] [Related]
19. 99mTcO(MAG2-3G3-dimer): a new integrin alpha(v)beta(3)-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics. Shi J; Wang L; Kim YS; Zhai S; Jia B; Wang F; Liu S Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1874-84. PubMed ID: 19484236 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of K(HYNIC)(2) as a bifunctional chelator for (99m)Tc-labeling of small biomolecules. Ji S; Zhou Y; Shao G; Liu S Bioconjug Chem; 2013 Apr; 24(4):701-11. PubMed ID: 23521129 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]